Boosting immune cells after lung cancer chemoradiation
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies whether a medicine called NKTR-255 can help restore and strengthen immune cells after standard chemoradiation for non-small cell lung cancer. The goal is to improve how well the body can fight the cancer after initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and have non-small cell lung cancer confirmed by biopsy/pathology
- Plan to receive definitive (curative-intent) treatment, and sign consent before any study procedures
- Have no other active cancers elsewhere (with limited exceptions like low-risk prostate or skin cancers)
- Have good blood/organ health: liver tests and kidney function must be within allowed limits
- Be able to function fairly well (ECOG 0–2) and follow study visits and consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment using your own immune cells (T cells) that are specially trained to find and attack lung cancer cells. It may help people with advanced or relapsed lung cancer who have not improved with standard treatments.
This trial tests giving radiation and immunotherapy together to people with advanced lung cancer that hasn't been treated yet. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests whether adding a NAD+ booster (NMN) to radiation and immunotherapy can help people with advanced lung cancer. It may improve the effectiveness of the treatment and help you live longer.
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
This trial tests whether combining two immunotherapy drugs (which help your immune system fight cancer) with a type of precisely targeted radiation (SBRT) is safe and effective for people with early-stage non-small cell lung cancer. If you qualify, you might receive a treatment that could boost your body's ability to destroy cancer cells.
This trial tests a new combination of chemotherapy, radiation, and immunotherapy (durvalumab) for people with stage III non-small cell lung cancer that cannot be removed with surgery. The goal is to see if giving a smaller, more focused radiation dose can be just as effective with fewer side effects.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.